How to start retatrutide begins with an asynchronous provider evaluation at TelosRX, followed by a low starting dose and careful titration over several weeks. This not-FDA-approved compounded triple agonist targets GLP-1, GIP, and glucagon receptors, subject to medical approval by a licensed provider.
Retatrutide is not semaglutide. It’s not tirzepatide. It engages three separate hormone receptors simultaneously — GLP-1 (appetite and digestion), GIP (insulin response and fat metabolism), and glucagon (energy expenditure). That triple action is what makes it mechanistically distinct from earlier GLP-1 compounds. It’s also why the titration schedule is more conservative.
This guide walks through every step in plain terms. What the compound is, how to get evaluated, how to inject it correctly, and how to manage the common side effects that catch new patients off guard.
Step 1: Understand What Retatrutide Is — and Isn’t
Retatrutide is a synthetic peptide agonist studied for metabolic health and body weight reduction. Phase 2 clinical data, published in the New England Journal of Medicine (2023), showed significant mean weight reduction in trial participants at 24 and 48 weeks across multiple dose arms. Phase 3 trials are ongoing through the TRIUMPH program at ClinicalTrials.gov.
It is not FDA-approved. It’s available as a compounded medication through licensed providers operating under federal compounding regulations. Those are clinical trial results — individual outcomes vary based on dose, diet, starting weight, and metabolic factors.
| Feature | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| Receptor targets | GLP-1, GIP, glucagon | GLP-1, GIP | GLP-1 only |
| FDA approval | Not FDA-approved (compounded) | Approved (Mounjaro/Zepbound) | Approved (Wegovy/Ozempic) |
| Trial stage | Phase 3 ongoing | Approved | Approved |
| Administration | Weekly subcutaneous injection | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Mechanism unique feature | Glucagon receptor agonism | Dual incretin effect | GLP-1 pathway only |
For a deeper look at what the triple-agonist mechanism means, see our overview: Retatrutide Weight Loss: Triple-Agonist GLP-1 Explained.
Step 2: Complete Your Asynchronous Provider Evaluation
You don’t need a scheduled video call. TelosRX operates as an asynchronous telehealth service — your intake is a structured health questionnaire covering your medical history, current medications, metabolic goals, and any relevant lab results. A licensed provider reviews your submission and makes an eligibility determination.
Retatrutide is subject to medical approval by a licensed provider. Not everyone qualifies. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2 (MEN 2), or known hypersensitivity to the compound. Your provider assesses these factors before issuing a prescription.
The intake takes about 10 minutes. Provider review typically happens within 24 hours. Start your private evaluation at TelosRX — no appointment needed.
Step 3: Start at the Lowest Titration Dose
Jumping to a higher dose early is the most common mistake with GLP-1-class compounds. The titration schedule exists to let your gastrointestinal system adapt gradually. Retatrutide has a more conservative starting dose than semaglutide or tirzepatide precisely because of the added glucagon receptor activity.
Research protocols used in Phase 2 trials began at 0.5 mg weekly, with uptitration steps every 4 weeks contingent on tolerability. Your licensed provider sets and approves your personal titration ladder via the TelosRX asynchronous review process — do not adjust your dose without provider guidance.
Typical titration milestones (Phase 2 research-informed ranges — your protocol may differ):
- Weeks 1–4: 0.5 mg weekly — starting dose, GI adaptation phase
- Weeks 5–8: 1 mg weekly — first uptitration if tolerated
- Weeks 9–12: 2 mg weekly — second step, provider-approved
- Weeks 13–20: 4 mg weekly — intermediate maintenance range
- Weeks 21+: 8–12 mg range — higher dose arms used in Phase 2 trials
Slower titration means fewer side effects and better long-term tolerability. Don’t treat these ranges as a race to hit the top dose. Your provider’s guidance takes precedence over any published range.
Step 4: Inject Correctly and Store Your Medication
Retatrutide is a subcutaneous injection — just under the skin, not into muscle. Common sites are the abdomen (2 inches from the navel), the outer thigh, or the back of the upper arm. Rotate sites weekly to prevent lipohypertrophy — a buildup of tissue that reduces absorption efficiency.
Injection procedure (subject to any specific instructions from your provider):
- Wash hands for at least 20 seconds before handling.
- Remove the syringe from refrigeration 15–20 minutes before injecting. Room-temperature medication reduces sting.
- Clean the injection site with an alcohol swab. Let it fully dry before injecting — wet alcohol causes unnecessary discomfort.
- Pinch the skin lightly with two fingers. Insert the needle at a 45–90 degree angle depending on your body composition and the needle gauge.
- Inject slowly and steadily. Remove the needle at the same angle it entered. Apply gentle pressure with a cotton ball — no rubbing.
- Dispose of the needle in an approved sharps container immediately after use. Never recap.
Storage: keep vials refrigerated between 36–46°F (2–8°C). Don’t freeze. If the solution appears cloudy, discolored, or contains particles, discard it and contact your provider before proceeding.
Step 5: Manage Early GI Side Effects
Most side effects with retatrutide appear in the first 4–8 weeks and involve the GI tract: nausea, reduced appetite, loose stools, and in some cases vomiting or constipation. These typically decrease as your body adapts. They’re more common during uptitration steps.
Three evidence-supported strategies to reduce early GI discomfort:
- Eat smaller meals more frequently. Large portions amplify nausea on GLP-1-class compounds. Aim for 3–4 smaller meals rather than 1–2 large ones, especially in the first month.
- Stay well-hydrated. Diarrhea and vomiting both carry dehydration risk. Keep water intake consistent — at least 8 cups daily, more if you’re experiencing GI symptoms.
- Avoid high-fat meals on injection day. Fat delays gastric emptying, which compounds GLP-1-driven nausea. Lighter meals the day of and the day after your injection reduce that overlap.
For a comprehensive breakdown of managing GLP-1-class side effects, see: GLP-1 Side Effects Management: What Research Shows.
If you experience persistent vomiting lasting more than 24 hours, severe abdominal pain, symptoms of dehydration, or unusual visual changes, message your provider immediately through the TelosRX patient portal. Don’t wait.
Ready to get started? Begin your asynchronous evaluation at TelosRX — a licensed provider reviews your intake within 24 hours.
Step 6: Track Progress and Follow Up Asynchronously
TelosRX doesn’t use scheduled appointments for routine check-ins. The follow-up process is asynchronous — you report progress, side effects, or concerns through the patient portal, and a licensed provider responds with guidance, dose adjustments, or lab orders as needed.
Track your weight weekly at the same time of day, same conditions. Don’t over-read week-to-week fluctuations — hydration, GI activity, and sleep all move the number. A 4-week trend is more informative than any single weigh-in.
Key clinical markers to review with your provider at 90 days: body weight, waist circumference, fasting glucose (if ordered), lipid panel (if ordered), and any persistent side effects. Document how your appetite and energy have shifted — this information helps your provider make informed titration decisions.
If you hit a weight-loss plateau, read our guide: GLP-1 Weight Loss Plateau: Why It Happens and What to Do.
Frequently Asked Questions
Is retatrutide FDA-approved?
No. Retatrutide is not FDA-approved. It’s available as a compounded medication through licensed providers operating under federal compounding regulations. Access requires a provider-issued prescription following an asynchronous medical evaluation, and approval is not guaranteed. Individual eligibility is assessed case by case.
How long does it take for retatrutide to work?
Appetite changes are often noticeable within 2–4 weeks at starting doses. Meaningful body composition changes typically emerge at 8–12 weeks. Phase 2 trial data tracked outcomes at 24 and 48 weeks — that time horizon reflects when the compound’s full effect becomes measurable. Individual results vary significantly.
What is the starting dose for retatrutide?
Phase 2 research protocols started participants at 0.5 mg weekly. Your licensed provider determines your specific starting dose and titration schedule based on your health profile. Do not self-adjust — all dose changes require asynchronous provider review and approval through the TelosRX platform.
Can retatrutide be taken with other medications?
Drug interactions must be reviewed by your provider. GLP-1-class compounds slow gastric emptying, which can affect the absorption timing of oral medications — especially those with narrow therapeutic windows. Disclose all current medications, supplements, and over-the-counter products in your intake questionnaire.
What happens if I miss a retatrutide injection?
If you miss a dose and it’s within 4 days of your scheduled injection day, take it as soon as you remember. If more than 4 days have passed, skip the missed dose and resume your regular schedule. Do not double your next dose. Message your provider through the portal with any questions about your schedule.
How does retatrutide compare to tirzepatide for weight loss?
Retatrutide adds glucagon receptor agonism to the dual GLP-1/GIP profile of tirzepatide. Phase 2 data showed higher mean weight reduction with retatrutide at higher dose arms compared to tirzepatide in comparable timeframes — but no head-to-head trial has been published. Both are subject to provider approval. Individual responses vary.
Who should not take retatrutide?
Individuals with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not use GLP-1 receptor agonists. Active pancreatitis, pregnancy, and certain GI conditions may also be contraindications. Your licensed provider assesses all eligibility factors during the asynchronous intake process.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.